EMTRICITABINE - Generic Drug Details

What are the generic sources for emtricitabine and what is the scope of patent protection?

Emtricitabine is the generic ingredient in eleven branded drugs marketed by Aurobindo Pharma Ltd, Cipla, Gilead, Apotex, Gilead Sciences Inc, Mylan, Lupin Ltd, Hetero Labs Ltd Iii, Amneal Pharms Co, Aurobindo Pharma, Chartwell Rx, Laurus, Macleods Pharms Ltd, Pharmobedient, Strides Pharma, Teva Pharms Usa, and Zydus Pharms, and is included in twenty-five NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

There are eighteen drug master file entries for emtricitabine. Three suppliers are listed for this compound. There are seven tentative approvals for this compound.

Summary for EMTRICITABINE

US Patents:	3
Tradenames:	11
Applicants:	17
NDAs:	25
Drug Master File Entries:	18
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	110
Clinical Trials:	542
Patent Applications:	7,710
Drug Prices:	Drug price trends for EMTRICITABINE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EMTRICITABINE
What excipients (inactive ingredients) are in EMTRICITABINE?	EMTRICITABINE excipients list
DailyMed Link:	EMTRICITABINE at DailyMed

See drug prices for EMTRICITABINE

Recent Clinical Trials for EMTRICITABINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
HIV Prevention Trials Network	PHASE2
National Institute on Drug Abuse (NIDA)	PHASE1
Johns Hopkins University	PHASE1

See all EMTRICITABINE clinical trials

Generic filers with tentative approvals for EMTRICITABINE

Applicant	Application No.	Strength	Dosage Form
		200MG; 300MG	TABLET; ORAL
		200MG	CAPSULE; ORAL
		120MG	TABLET; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for EMTRICITABINE

Drug Class	Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors

Medical Subject Heading (MeSH) Categories for EMTRICITABINE

Anti-HIV Agents

Antiviral Agents

Reverse Transcriptase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for EMTRICITABINE

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for EMTRICITABINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EMTRIVA	Capsules	emtricitabine	200 mg	021500	1	2012-07-16

US Patents and Regulatory Information for EMTRICITABINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	TABLET;ORAL	214095-001	Jan 30, 2026	AB	RX	No	No
Zydus Pharms	EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	212689-002	Jul 1, 2021	AB	RX	No	No
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021752-004	Mar 10, 2016	AB	RX	Yes	No

Expired US Patents for EMTRICITABINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead	EMTRIVA	emtricitabine	SOLUTION;ORAL	021896-001	Sep 28, 2005
Gilead	EMTRIVA	emtricitabine	CAPSULE;ORAL	021500-001	Jul 2, 2003
Gilead	EMTRIVA	emtricitabine	CAPSULE;ORAL	021500-001	Jul 2, 2003

EU/EMA Drug Approvals for EMTRICITABINE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Gilead Sciences Ireland UC	Emtriva	emtricitabine	EMEA/H/C/000533Emtriva is indicated for the treatment of HIV-1 infected adults and children in combination with other antiretroviral agents.This indication is based on studies in treatment-naive patients and treatment-experienced patients with stable virological control. There is no experience of the use of Emtriva in patients who are failing their current regimen or who have failed multiple regimens.When deciding on a new regimen for patients who have failed an antiretroviral regimen, careful consideration should be given to the patterns of mutations associated with different medicinal products and the treatment history of the individual patient. Where available, resistance testing may be appropriate.	Authorised	no	no	no	2003-10-24

Market Dynamics and Financial Trajectory for Emtricitabine

Last updated: February 20, 2026

What is the current market size and growth rate for emtricitabine?

Emtricitabine is a reverse transcriptase inhibitor used primarily in HIV treatment. The global market value for emtricitabine was estimated at approximately USD 1.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of around 3-5% from 2023 to 2030, driven by increasing HIV prevalence and expanding treatment access in emerging markets.

The forecast considers the broader antiretroviral therapy (ART) segment, where emtricitabine's combined use with other drugs (e.g., tenofovir) significantly influences sales volume. The market's regional distribution shows North America accounting for roughly 40% of sales, Europe 25%, Asia Pacific 20%, and the rest of the world 15%.

What are key factors shaping the supply and demand of emtricitabine?

Supply factors:

• Patent expirations in major markets: The patent for Viread (tenofovir) expired in 2020 in the U.S., leading to increased competition and lower prices for combination therapies incorporating emtricitabine.
• Manufacturing capacity: Consolidation among generic producers has increased efficiency, reducing costs and ensuring stable supply.
• Regulatory approvals: New formulations and biosimilars are in development, potentially increasing overall supply.

Demand factors:

• HIV prevalence: Approximately 38 million people globally living with HIV in 2022, with a significant portion on ART regimens containing emtricitabine.
• Treatment guidelines: Recommendations from WHO and national agencies favor combination therapies that include emtricitabine, maintaining steady demand.
• Pricing and access: Lowered drug prices via generic competition enable broader access in low- and middle-income countries, expanding the patient base.

How do patent protections and generic competition influence financial outcomes?

Patents on branded emtricitabine formulations, granted in the early 2000s, normally protected exclusive rights until 2020-2025. Following patent expiry, generic manufacturers entered markets at substantially reduced prices, causing branded sales to decline.

In low-income countries, generic versions constitute over 80% of the market. Companies with early market entry enjoy increased volume sales, but profit margins have contracted due to price erosion. The shift has compressed the revenue per treatment course, impacting expected financial trajectories for originators.

What are the major players and their market share?

Company	Market Share (Estimate, 2022)	Key Strategies
Gilead Sciences	50%	Focus on combination therapies and patent protections
Teva Pharmaceuticals	25%	Extensive generic portfolio; cost leadership
Mylan (now part of Viatris)	10%	Price competition; expanding access in emerging markets
Others	15%	Regional players; biosimilars in development

Gilead retains a dominant position primarily through its combination therapies (e.g., Descovy, Truvada), which include emtricitabine. Generics suppliers focus on commoditized emtricitabine APIs and formulations.

What are the R&D and regulatory trends affecting emtricitabine?

• Fixed-dose combination (FDC) formulations: Companies are developing FDCs with improved tolerability and simplified regimens, promising increased adherence.
• New delivery methods: Long-acting injectables and implantable devices are under investigation, though not yet commercially available.
• Patent challenges: Legal disputes over secondary patents may influence market exclusivity periods.
• Regulatory approval pathways: Emergency use authorizations and accelerated approval processes in some regions may accelerate market access for newer formulations.

What is the outlook for future revenue streams?

Revenue projections depend on several factors:

• The extent of patent expirations and generic entry: The horizon for emtricitabine’s branded revenues extends until approximately 2025, after which generic market share dominates.
• Innovation: Development of long-acting formulations could shift expenditure toward new products, potentially rejuvenating revenue streams for pioneer companies.
• Global health initiatives: Funding from organizations like the Global Fund and Gavi supports access expansion, maintaining demand in underserved regions.
• Competition: Price wars and biosimilar entries may continue to pressure margins but also expand volume.

Key Takeaways

• The global emtricitabine market totaled ~$1.2 billion in 2022, with expected growth driven mostly by demand in HIV therapy.
• Patent expirations have led to increased generic competition, significantly reducing revenue for originators post-2020.
• Regional disparities favor North America and Europe in revenue concentration; low-income countries expand volume through generics.
• Innovation in drug delivery and combination regimens offers future growth avenues.
• Major manufacturers include Gilead (leading), Teva, and Viatris, with shifting market share following patent cliff timelines.

FAQs

1. How does patent expiry impact emtricitabine revenues? Patent expiration opens markets to generics, lowering prices and reducing revenues for original developers.

2. Are there any new formulations of emtricitabine under development? Yes, long-acting injectables and FDCs are under clinical trials, aiming to improve adherence and treatment outcomes.

3. What regions show the highest growth potential for emtricitabine? Emerging markets in Africa, Asia, and Latin America offer significant growth due to expanding HIV treatment programs.

4. How does generic competition in low-income countries influence pricing? Greater competition drives prices down, making emtricitabine formulations more affordable and accessible.

5. What are key risks affecting the future market for emtricitabine? Patent litigation, regulatory delays for new formulations, and unpredictable funding for global health initiatives pose risks to revenue stability.

---

References

[1] MarketResearch.com. (2023). Global HIV/AIDS pharmaceuticals market analysis.
[2] WHO. (2022). Global HIV/AIDS update.
[3] Gilead Sciences. (2022). Annual report.
[4] Teva Pharmaceuticals. (2022). Market overview and strategy report.
[5] Statista. (2023). HIV/AIDS treatment market data.